Legend Biotech Corporation
LEGN
$35.46
-$0.17-0.48%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 38.54% | 115.04% | 134.56% | 66.60% | 151.27% |
| Total Other Revenue | -99.88% | -97.30% | 446.34% | 1,378.95% | 3,746.03% |
| Total Revenue | 36.74% | 107.52% | 134.73% | 66.86% | 154.36% |
| Cost of Revenue | 20.37% | 11.28% | 29.12% | 8.37% | 26.94% |
| Gross Profit | 150.64% | 135.30% | 113.92% | 121.27% | 142.53% |
| SG&A Expenses | 23.28% | 28.99% | 33.25% | 61.72% | 33.01% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 21.20% | 15.98% | 30.40% | 22.29% | 28.62% |
| Operating Income | 47.87% | 57.03% | 38.08% | 23.96% | 59.77% |
| Income Before Tax | -594.48% | -65.80% | 127.59% | -93.43% | 90.96% |
| Income Tax Expenses | 157.52% | 35,620.00% | 813.49% | 1,639.93% | -22.07% |
| Earnings from Continuing Operations | -589.05% | -68.78% | 118.15% | -101.46% | 90.86% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -589.05% | -68.78% | 118.15% | -101.46% | 90.86% |
| EBIT | 47.87% | 57.03% | 38.08% | 23.96% | 59.77% |
| EBITDA | 49.78% | 57.76% | 39.09% | 24.34% | 61.99% |
| EPS Basic | -583.63% | -67.18% | 118.00% | -99.53% | 91.23% |
| Normalized Basic EPS | -588.78% | -61.38% | 130.38% | -91.54% | 91.33% |
| EPS Diluted | -580.90% | -67.18% | 117.98% | -99.53% | 91.23% |
| Normalized Diluted EPS | -588.78% | -61.38% | 127.65% | -91.54% | 91.33% |
| Average Basic Shares Outstanding | 0.84% | 0.97% | 0.82% | 0.96% | 4.19% |
| Average Diluted Shares Outstanding | 0.84% | 0.97% | 10.77% | 0.96% | 4.19% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |